Modified Binary Toxin Receptor for Targeted Intracellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering bioactive molecules into mammalian cells, particularly larger molecules like proteins and cytotoxins, face challenges such as requiring large quantities, limited selectivity, and inefficient intracellular delivery, often resulting in accumulation in endosomes rather than the cytosol.
Innovation Solution
Development of a cell-specific delivery system using modified binary bacterial toxins, where the B component binds to a targeted cellular receptor and the A component is translocated through the cell membrane to deliver therapeutic molecules, such as cytotoxins, into the cytosol, utilizing receptor-ablated pore-forming binary toxins fused with specific ligands to target cancer cells or immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current delivery methods are used to deliver bioactive molecules into mammalian cells, then delivery can be achieved, but large quantities of sample are required and selectivity is limited
Solution Approach 1:
The patent uses modified binary bacterial toxins as intermediary delivery vehicles. The B component acts as a mediator that binds to specific cell surface receptors and facilitates the translocation of the A component (carrying the therapeutic molecule) into the cell cytosol. This intermediary system enables highly efficient and selective delivery of bioactive molecules without requiring large quantities of sample.
2Reliability
If current delivery methods are used, then delivery into cells can be achieved, but the molecules tend to accumulate in endosomes rather than reaching the cytosol
Solution Approach 1:
The patent exploits the natural endocytic pathway and endosomal acidification (which would normally trap molecules in endosomes) as a beneficial mechanism. The modified toxin uses the acidic endosomal environment to trigger conformational changes that facilitate membrane translocation, converting the harmful endosomal trapping into a beneficial translocation mechanism that delivers the therapeutic molecule directly to the cytosol.
3Reliability
If binary bacterial toxins are modified to bind specific cell receptors, then selectivity and delivery efficiency are improved, but the system complexity increases
Solution Approach 1:
The patent divides the toxin into separate functional components (A and B components) that can be independently engineered and optimized. The B component is modified to bind specific cell surface receptors for targeted delivery, while the A component carries the therapeutic molecule. This segmentation allows for modular design and reduced overall system complexity compared to creating entirely new delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and selective delivery of therapeutic proteins and cytotoxins into targeted cells, including cancer cells, with high specificity and efficacy, reducing the number of targeted cells or inducing cell death, while minimizing off-target effects.
Implementation Method 1
the B component binds to a targeted cellular receptor on a target cell
Implementation Method 2
the A component interacts with the B component to deliver a biologically active molecule to the target cell cytosol via translocation through the cell membrane
Data Source
AI summary
We described a novel system of targeted cell therapy with a protein toxin, such as anthrax toxin, that has been modified to re-direct it to a desired cell target instead of its natural cell target. The system can be used for, e.g., targeted killing of undesired cells in a population of cells, such as cancer or overly active immune system cells.